NCT04740190View on ClinicalTrials.gov

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions
Recurrent GliomaRecurrent GlioblastomaPoly ADP Ribose Polymerase (PARP) InhibitorPTEN Gene InactivationIDH Mutation
Interventions
DRUG

Talazoparib

low dose whole brain radiation, followed by combination talazoparib and carboplatin

Trial Locations (1)

Unknown

Department of Clinical Oncology, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT04740190 - Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd | Biotech Hunter | Biotech Hunter